



Sponsorship & Exhibitors **Prospectus** 











## TABLE OF CONTENT

About the SIU	3
SIU Governance	3
Who are SIU Members?	3
SIU Regional Meetings in Urological Care: Evidence Based Update	es 6
Invitation Letter from the Meeting Chair	6
Planning Committee	7
General Information	9
COVID-19 Safety Measures	9
Statement of Need	10
Background	10
Programme Description	11
Programme At-a-Glance	12
Learning Objectives:	13
Opportunities for Partnership	15
À la Carte Opportunities	16
Exhibit Hall Schedule	17
Exhibit Hall Floor Plan	17
Participants Registration fees	18
Group Registration	18
Sponsorship Confirmation Form	19
Appendix A – Programme Agenda and Suggested Faculty	21
Appendix B – Literature Review	27
References	30

## About the SIU







The Société Internationale d'Urologie (SIU) is an international not-for-profit medical society, serving urologists, trainees, and affiliated healthcare professionals from over 130 countries.

We are proud to include more than 10,000 members as part of the SIU Community and we continue to represent a spectrum of geographical and practice settings in our membership and activities. It is through this diversity of representation that the Society can provide a unique and valuable offering in education, research, networking, and philanthropy to urologists from around the world.

### THE SIU CONNECTS UROLOGISTS AROUND THE WORLD THROUGH ITS:

- Annual congress and intuitive virtual congress platform, SIU@U
- eLearning portal, SIU Academy® an extensive library of educational programmes and a hub for live virtual events
- New, open-access and free academic journal, SIUJ

Astallate A Astallate A . Later Late

- Training scholarships, tailored programming for trainees and young urologists, and collaborative philanthropic activities, and
- uCARE, a research platform powered by a global council.







## SIU Governance

The SIU is governed by a Board of Directors comprised of 27 urologists from 15 countries.



PRESIDENT



PRESIDENT-FLECT



VICE PRESIDENT



المعامل المعام

PAST PRESIDENT AND NOMINATING COMMITTEE CHAIR



GENERAL SECRETARY



GENERAL SECRETARY-ELECT



**TREASURER** 



OFFICE OF EDUCATION OFFICE OF RESEARCH





OFFICE OF RESEARCH-ELECT



**PUBLICATIONS** 



CONGRESS ORGANIZING



CORPORATE DEVELOPMENT



MEMBERSHIP AND INTERNATIONAL RELATIONS-AMERICAS



MEMBERSHIP AND INTERNATIONAL RELATIONS-AFRICA AND MIDDLE EAST



MEMBERSHIP AND INTERNATIONAL RELATIONS-ASIA-PACIFIC



MEMBERSHIP AND INTERNATIONAL RELA-TIONS-EUROPE



INNOVATORS



INSTITUTES AND SCHOLARSHIPS



SCIENTIFIC PROGRAMME CO-CHAIR



SCIENTIFIC PROGRAMME CO-CHAIR



RESEARCH COMMITTEE



**URO TECHNOLOGY** TRAINING



NATIONAL SOCIETY DELEGATE REPRESENTATIVE



NATIONAL SOCIETY DELEGATE REPRESENTATIVE



GENERAL ASSEMBLY REPRESENTATIVE



GENERAL ASSEMBLY REPRESENTATIVE

About the SIU

## SIU MEMBERS: THE HEART OF THE SIU

SIU members make up a true cross-section of international urology. The **diverse geography** and **subspecialty training** of our members allows for unique perspectives which ensure that the needs of the global community are served by the programmes and initiatives set forth by the SIU Board of Directors.

The SIU is proud to now have 56 national society delegates and 33 group member societies. **6,465** Urologists

3,484 Residents **69**Affiliate and
Associate Members

The SIU has **10,018 members** from over **130 countries** 



Stone Disease

**BPO/LUTS** 

18%

Andrology

**Diagnostic Urology** 

## SIU Regional Meetings in Urological Care: Evidence Based Updates



الفيار المنافية المنا





## Invitation Letter from the Meeting Chair

Dear Friends and Colleagues,

I am thrilled to announce the launch of a new SIU initiative: Regional Meetings in Urological Care. Regional meetings offer the unique opportunity to bring the high-quality education that attendees have come to expect from an SIU Congresses to a smaller, more intimate setting where regional perspectives can be amplified.

While many have us have gone nearly two years without in-person meetings, the SIU 2021 Congress this fall in Dubai demonstrated that it is feasible to provide a safe environment for face-to-face networking and learning in the COVID-era. The ease of connecting online for educational purposes has proven most valuable in recent years; however, the lack of human interaction and exchange has been felt deeply by urologists around the world. SIU aims to bring urologists together. This Regional Meeting is just one more way in which we will accomplish this goal, and your participation as our Industry Partner is integral to our success.

With the assistance of the expert scientific programme committee, Drs. Franck Bladou (France), Ranan Dasgupta (United Kingdom), Mauro Gacci (Italy), Stavros Gravas (Cyprus), Athanasios Papatsoris (Greece), we have put together a concise and relevant programme that addresses the most pertinent needs of urologists in the region, and beyond. While we anticipate that nearly 500 participants will join us in person, all content will also be accessible via our dynamic and interactive virtual platform for those who cannot make it in person.

Thank you, in advance, for your valuable contribution to this important educational endeavour. We look forward to welcoming you in Istanbul for what will no doubt be another successful SIU hybrid event.

Sincerely,

Jean de la Rosette, Turkey

Chair, SIU 2022 Regional Meeting on Urological Care

SIU Regional Meetings in Urological Care: Evidence Based Updates

## SIU Regional Meeting in Urological Care

June 10-12, 2022 / Istanbul

المنافع الماريخ الماريخ المارية الماريخ المارية الماريخ الماريخ الماريخ الماريخ الماريخ الماريخ الماريخ الماريخ







## Planning Committee



Chair: Jean de la Rosette, Turkey

SIU General Secretary

Dr. Jean de la Rosette is a professor of urology at Istanbul Medipol University, in Turkey, and professor at the University of Amsterdam, the Netherlands.

Dr. de la Rosette completed his medical degree and urology residency at St. Radboud University Hospital in Nijmegen, the Netherlands. His main fields of interest are minimally invasive surgery and endourology with a special focus on ablative treatments and urological ultrasound. He is past Chairman of the European Association of Urology (EAU) Section of Uro-Technology (ESUT) and past board member of the Society of Endourology. Dr. de la Rosette is past Chairman of the EAU working party on Benign Prostatic Hyperplasia (BPH) guidelines. He has co-authored more than 700 peer-reviewed publications and has authored many book chapters. He is a member of various urological societies and, since 2016, holds the position of General Secretary of the Société Internationale d'Urologie (SIU).



Franck Bladou, France

SIU Membership & International Relations Chair (Europe)

Dr. Franck Bladou is a full professor of urology, working at Pellegrin Tripode University Hospital and University of Bordeaux, in France. His main interest is uro-oncology with specific dedication to surgical innovation, such as robot-assisted

procedures, ablative and focal therapies for prostate cancer, 3D-reconstruction, virtual and reality-augmented surgery, prostate cancer imaging, and environmental impact of surgical modalities.

Dr. Bladou is an experienced urologist who has worked at the Paoli-Calmettes Cancer Center and University Hospital in Marseilles, France, and as a full professor of urology and head of the Urology Department and the Herbert Black Chair in Surgical Oncology at McGill University in Montreal, Canada, prior to his current position in Bordeaux.

Dr. Bladou is the present Director of Surgical Services at the Pellegrin Tripode Hospital and is actively involved in educating residents and fellows in urology. As an elected member of the French Urological Association (AFU) Board, Dr. Bladou is involved in the international committee and the sustainable development committee of the AFU.



## Ranan Dasgupta, United Kingdom

الأفينان وأكارات

SIU Research Committee Chair

Mr. Ranan Dasgupta is appointed at the Imperial College Healthcare (London) to lead comprehensive stone management, including percutaneous nephrolithotomy (PCNL), ureteroscopy (URS), external shockwaye lithotripsy (FSWL), and

shockwave lithotripsy (ESWL), and metabolic stone disease. His interests also include the management of benign prostatic hyperplasia (BPH) with laser enucleation, implants, and arterial embolization, as well as upper tract urothelial cancer.

Mr. Dasgupta wrote his thesis on neural control of voiding, which provided the proof of concept for studies in cannabinoids, botulinum toxin, and sildenafil. He also has a strong clinical research experience and was the principal investigator in 4 randomized controlled trials.

Mr. Dasgupta has published over 50 first-author papers and 10 book chapters. He has international experience as faculty for live surgery and has been the invited speaker for several lectures. He is a board-certified examiner at both undergraduate (MBBS) and postgraduate FRCS(Urology) levels.



Mauro Gacci, Italy

SIU Consensus and Education

Dr. Mauro Gacci is the Medical Director of the Unit of Robotic Surgery, Minimally Invasive Surgery and Kidney Transplantation at the University Hospital Careggi, Florence, Italy. He qualified in

medicine in 1997, became an accredited urologist in 2002, and has been a staff member of University Hospitals Careggi since 2004.

Dr. Gacci is a member of the European Association of Urology (EAU) Guidelines working group on non-neurogenic male lower urinary tract symptoms (LUTS), including benign prostatic obstruction. He has authored the International Consultation of Urologic Disease (ICUD) Guideline on Male Lower Urinary Tract Dysfunction. He is a member of the

SIU Regional Meetings in Urological Care: Evidence Based Updates

## SIU Regional Meeting in Urological Care

June 10-12, 2022 / Istanbul

All the standing of the standi








committee on LUTS of the Société Internationale d'Urologie (SIU) Academy. Dr. Gacci is an active member of many international and national scientific societies, including the EAU, SIU, Italian Society of Urodynamics (SIUD).

Dr. Gacci's research interests include preclinical, medical, and surgical studies on LUTS due to benign prostatic hyperplasia (BPH), prostate cancer, and radical prostatectomy; robotic surgery; and quality of life after oncologic surgery, comprising post-prostatectomy erectile dysfunction and incontinence. He has authored 290 indexed publications, including textbooks of urologic surgery and international guidelines, with an H-Index of 49.

He is a reviewer for several urologic and non-urologic journals including European Urology, Journal of Urology, Urology, The Prostate, Prostate Cancer and Prostatic Disease, British Journal of Urology, World Journal of Urology, Urologia Internationalis, Journal of Sexual Medicine, and the Asian Journal of Andrology.





medical degree and doctorate from University of Athens in Greece and completed a fellowship in Endourology at the University Hospital Nijmegen in the Netherlands.

Dr. Gravas is a peer reviewer of numerous journals, including European Urology, Journal of Urology, British Journal of Urology International, Urology, Journal of Endourology, Current Urology, Clinical Drug Investigation, and Journal of Medical Case Reports. He is the section editor of New Technologies in Journal of Endourology.

Dr. Gravas is a founding member of the Clinical Research Office of Endourological Society representing Europe and is a member of the board of directors of Société Internationale d'Urologie (SIU) and past member of the board of directors of the Endourological Society (2008–2012). He was the chair of Education and Consensus of SIU, chair-elect of the SIU Education Office and chairman of the EAU Guidelines Working Group on male LUTS.

He is the recipient of numerous awards and honors including the Maria and Pantelis Laimos Foundation scholarship (1997, 1998, 2002), SIU award for Outstanding Video Webcast and the award of Outstanding Contributor in Melbourne (2015).



## Athanasios Papatsoris, Greece

SIU Academy Committee Member

ا ( فیلیما الاین

Professor Athanasios Papatsoris graduated from Patras School of Medicine with an honorary scholarship and from the same University he obtained a MSc. Another MSc was obtained from the Hellenic Open University

entitled: Health Management. His PhD thesis was completed in the 2nd Department of Urology of Athens University. He was trained in Urology in London and in Athens, where he was certified as a Urological Surgeon. Thereafter, in London, he completed a two year Endourology fellowship (SpR level, recognized by the Endourological Society. Also, he completed a clinical fellowship in Laparoscopy in Le Mans, France, supported by the EUSP. Furthermore, for one year he served as an honorary Consultant in Urology at Royal London Hospital, Barts Health NHS Trust. Now he holds honorary contracts at Addenbrooke's Hospital, Cambridge and Imperial College, London and he is Faculty member of Cambridge Medical Academy. He obtained his FEBU degree in 2007 and since then he is a FEBU examiner and the last years he is the Vice Chairman of the EBU Examination Committee.

Dr. Papatsoris is a Full Professor of Urology at the 2nd Department of Urology, School of Medicine, Sismanoglio General Hospital, Athens Greece. Also, he is a Visiting Professor of Urology at the Lebanese University and Scientific Collaborator of the European University of Cyprus. Moreover, he is an Assoc. Board member of ESOU (Prostate Cancer Committee), EULIS, ESUT, ESAU, SEGUR and U-Merge. He is the EBU National Delegate, uCARE SIU Board member and SIU Academy Endourology Board member. Also, for four years he was the Secretary of the Hellenic Urological Association, the Vice Chairman of the Section of Endourology – Laparoscopy, while now he is the Chairman of the Section of Oncological Urology as well as Board Member of Hellenic Urological Association. Furthermore, he is a Board member of the IMBE and the Secretary General of the Hellenic Genito-Urinary Cancer Group.

Prof. Papatsoris H-Index is 40 with more than 230 publications in PubMed and with more than 5000 citations. He is a member of the Editorial Board of more than 30 medical journals and he has been invited as faculty in many international congresses, workshops, intensive courses and live Endourology surgeries. Recently, he won the "Arthur Smith" award from the Endourological Society.

SIU Regional Meetings in Urological Care: Evidence Based Updates



Autolite Autolite





## General Information

## Meeting Dates

June 10-12, 2022

## Meeting Venue

Renaissance Polat Istanbul Hotel TURKEY - Yeşilyurt, Sahil Yolu Cd. No:2, 34149 Bakırköy/İstanbul

## CME Accreditation

The "SIU Regional Meeting in Urology Care" has been submitted to the European Accreditation Council for Continuing Medical Education (EACCME®) and is awaiting CME approval.

## Accommodation at the Meeting Venue

### Renaissance Polat Istanbul Hotel

\*Rates are quoted per single room, per night

Room Rate: € 135

## COVID-19 Safety measures

The SIU constantly monitors the rapidly evolving global health landscape in light of the COVID-19 pandemic and is confident that it can continue to host safe in-person events to bring urologists together.

Some of the precautions taken by the Renaissance-Polat Istanbul hotel include:

- · Verification of proof of negative PCR test results for all registered participants
- Mandatory masking within the hotel vicinity (only exceptions will be when guests are seated to eat or drink in designated areas)
- · Temperature will be taken for all registered participants upon entry to event
- Physical distancing of at least 1 metre must be maintained between people from different households
- Restaurants, the fitness center, and other common areas have been carefully arranged to comply with social distancing rules
- · Hand sanitization stations are available throughout the venue
- · All high-touch areas such as elevator buttons and door handles are frequently disinfected
- All staff are required to wear a face mask as part of their uniform. Transparent plexiglass shields are placed in the restaurants

For updates on COVID-19 protocols and regulations, please visit the Turkish Airlines' website:

https://www.turkishairlines.com/en-tr/announcements/coronavirus-outbreak/turkey-travel-rules/

## Meeting Organizing Bureau

### **BROS Congress, Incentive & Events**

Sağlam Fikir Sok. Esen Palas Apt. A Blok No: 2 D: 9 Şişli / İstanbul E-mail: bilge.yuksel@brosgroup.net

SIU Regional Meetings in Urological Care: Evidence Based Updates









## Statement of Need

Conferences are widely recognized as a central component of the academic and professional life of various disciplines, providing an important environment for the dissemination of research and technological advances, networking, and establishment of collaborations and scholarship opportunities. In Urology, conferences are also an essential aspect of continuing medical education (CME) and offer physicians and trainees the opportunity to keep up-to-date with current and emerging clinical practices as well as meet board certification requirements.<sup>2</sup>

Over the last 18 months, the travel and social distancing restrictions put in place to limit the spread of COVID-19 have had a dramatic impact on medical conferences and the way physicians and trainees fulfill their CME needs. Most major urological societies worldwide were forced to cancel their inperson conferences in 2020–2021 and move all meetings to a virtual-only format. While virtual conferences may have provided a more accessible and less costly alternative to in-person meetings, they lacked the critical human interaction component that is intrinsic of face-to-face events.<sup>3</sup>

In 2021, the SIU was the first urological society to host an in-person international conference, proving a return to face-to-face events during the pandemic is presently feasible while adhering to rapidly evolving health and safety regulations. The success achieved by the 4lst Congress of the SIU was in part thanks to its hybrid format. Select sessions were live streamed on *SIU@U*, the online congress platform, which allowed greater accessibility to the urological community worldwide. At the same time, the face-to-face component also promoted lively interactions among the faculty and the audience attending in person. With a progressive return to in-person events, hybrid conferences may become the preferred format for urologists to easily access the latest developments in medical research and support a safe environment for face-to-face networking and learning.<sup>2,3</sup>

## Background

New developments in imaging, surgical and minimally invasive interventions have contributed to optimizing the management of urological conditions and improving patient outcomes. In particular, advances in technology, instrumentation, and technique for the management of stone disease, urologic cancers, and benign prostatic hyperplasia (BPH) have provided new opportunities for treatment and influenced the standard of care in recent years.

A complete needs assessment literature review is available in Appendix B.

SIU Regional Meetings in Urological Care: Evidence Based Updates

المار الأعلى والأواق الأراب الأراب المراب ال



الفروا المرااء المراء الم





## Programme Description

## SIU Regional Meetings in Urological Care – Evidence Based Updates

The purpose of the Regional Meetings in Urological Care is to provide an update on the management of common urological conditions based on current and emerging evidence and clinical practice guidelines. Over the course of three days, an international faculty composed of experts in different urological subspecialties and early-career urologists will discuss recent advances in surgical and minimally invasive interventions for the management of urological conditions in four different modules. The topics discussed in each module can be easily adapted in response to the educational needs of SIU members in the region where the meeting is held.

The first Regional Meeting in Urological Care is set to take place in Istanbul, Turkey, in June 2022. This meeting will feature modules on the management of urinary stones, prostate cancer, bladder cancer, and BPH. Each module will be divided into a five-part programme:

- 1. **Semi-Live Session:** using pre-recorded videos of interventions/surgical procedures in real-life patients, the experts will present their approach and discuss important technical aspects for performing urological procedures.
- **2. Evidence-Based/Guidelines Session:** building on the semi-live session, early-career urologists will provide a critical reflection on the procedures and clinical cases, according to evidence-based data and clinical practice guidelines.
- **3. Debate Session:** two experts will take the position either in favour or against controversial topics in urological management in a lively debate.
- **4. Masters of Disaster Session:** following moderation by expert urologists, six early-career urologists will examine and discuss the management of complex clinical cases.
- **5. Future Perspectives Session:** an expert will provide their perspective on emerging technologies, instrumentation, and approaches for the management of urological conditions.

Overall, the Regional Meetings in Urological Care will include a practical and dynamic programme to discuss critical advances and provide best practices in the management of urological conditions that are aimed not only to support the educational needs of experienced urologists but also of early-career physicians and trainees. The Regional Meetings aim to bring together close to 1,000 participants (in-person and online) who are actively involved in urological care.

SIU Regional Meetings in Urological Care: Evidence Based Updates

Autol lite Autol lette Autol lette Autol



المالية المالية المالية المالية المالية المالية المالية المالية المالية المالية المالية المالية المالية المالية





## Programme At-a-Glance

Friday, June 10	Session I – Endourology
13:00-14:30	Semi Live: How I Do It/Points of Technique in Urinary Stones Management
15:00-16:30	Evidence-Based/Guidelines: How to Best Treat Urinary Stones
16:30-17:00	Debate: Is Mini PCNL Going to Fade Away?
17:00-18:00	Masters of Disaster in Endourology
18:00-18:15	Future Perspectives: Artificial Intelligence and Stone Management
Saturday, June 11	Session II – Oncology – Prostate Cancer
08:00-09:30	Semi-Live: How I Do It/Points of Technique in Prostate Cancer Treatment
10:00-11:30	Evidence-Based/Guidelines Session: How to Best Treat Prostate Cancer
11:30-12:00	Debate: Fusion versus Cognitive Biopsies - Is the New Gold Standard?
12:00-13:00	Masters of Disaster in Prostate Cancer
13:00-13:15	Future Perspectives: 3D Reconstruction and Virtual RP
Saturday, June 11	Session III – Oncology – Bladder Cancer
14:00-15:30	Semi-Live Session: How I Do It/Points of Technique in Bladder Cancer Treatment
16:00-17:30	Evidence-Based/Guidelines: How to Best Treat Bladder Cancer
17:30-18:00	Debate: Is TURBT en bloc the New Gold Standard?
18:00-19:00	Masters of Disaster in Bladder Cancer
19:00-19:15	Future Perspectives: MRI staging of bladder TCC – VI-RADS
Sunday, June 12	Session IV – BPH
08:00-09:30	Semi-Live: How I Do It/Points of Technique in BPH Management
10:00-11:30	Evidence-Based/Guidelines: How to best treat BPH
11:30-12:00	Debate: Is Preservation of Ejaculatory Function Relevant?
12:00-13:00	Masters of Disaster in BPH
13:00-13:15	Future Perspectives in BPH Management
Sunday, June 12	Session V – Men's Health Luncheon Symposium
13:30 – 13:32	Welcome & Introduction
13:32 – 13:42	Upgrading the Clinical Practice by setting up a Men's Health Clinic
13:42 – 13:54	Hypogonadism: from diagnosis to management
13:54 – 14:06	Management of stable phase Peyronie's disease
14:06 – 14:21	Management of post-prostatectomy climacturia
14:31 – 14:44	Surgical treatment of varicocele: which approach is best?
14:44 – 14:56	Surgical management of priapism
14:56 – 15:08	Penile fracture: diagnosis and management
15:18 – 15:30	Setting up a penile implant centre
15:30 – 15:42	Step-by-step approach to IPP placement
15:42 – 15:54	IPP infection prevention and treatment strategies
16:00	Closing remarks

SIU Regional Meetings in Urological Care: Evidence Based Updates



الأعلى والأراني الأسالي والأران والمالي والمال





## Learning Objectives:

## **Overall Learning Objectives**

At the end of the Regional Meeting in Urological Care, participants should be able to:

- Recognize treatment approaches for complicated urinary stone disease in special situations, using ureteroscopy and percutaneous surgery.
- Assess adequate treatment for localized prostate cancer with different curative surgical procedures, including radical prostatectomy and focal therapy.
- Examine evidence-based approaches for the diagnosis, treatment, and follow-up of urothelial carcinoma of the upper and lower urinary tract.
- · Identify adequate management options for BPH treatment using surgical and minimally invasive alternative procedures.
- Recall the management approach for complications associated with endourological and urooncological procedures for the treatment of benign and malignant urological conditions.

### Session I - Endourology

At the end of the Endourology Session, participants should be able to:

- Examine expert surgical steps and points of technique during the management of challenging stone cases.
- Recall how to best treat urolithiasis accord to evidence-based medicine and clinical practice guidelines.
- Identify how to prevent, diagnose, and manage serious complications associated with stone surgery.
- Recognize the emerging role of artificial intelligence in the management of urolithiasis.

### Session II - Prostate Cancer

At the end of the Prostate Cancer Session, participants should be able to:

- Identify factors favouring the choice of transperineal vs. transrectal prostate biopsy and the step-by-step technique to perform the procedure.
- Assess the current use of fusion biopsies in prostate cancer management, based on recently published software data.
- Recognize surgical steps for robotic and transperineal radical prostatectomy, both in the primary and salvage setting, through state-of-the-art surgical demonstrations and discussions.
- Recall patient selection criteria and surgical technique for focal therapy of prostate cancer, according to recently published data.

SIU Regional Meetings in Urological Care: Evidence Based Updates

المار المعلى الأعلى الأعلى المعلى 


الفيني المالي المنابع المالي المنابع ا





### Session III - Bladder Cancer

At the end of the Bladder Cancer Session, participants should be able to:

- · Recall contemporary techniques for endoscopic resection of bladder tumours.
- · Recognize recent advances in the diagnosis and treatment of upper tract urothelial tumours.
- Evaluate the role of current imaging strategies in staging of bladder cancer.
- Identify adequate management of complications associated with endoscopic treatment of urothelial carcinoma of the upper and lower urinary tract.

### Session IV - BPH

At the end of the BPH Session, participants should be able to:

- Recall the surgical steps and points of technique of available invasive treatment approaches for the management of BPH.
- Critically examine the clinical evidence and updated clinical practice guidelines on surgical and minimally invasive management of BPH.
- · Contrast the pros and cons of ejaculation preservation in treatment decision-making of BPH.
- · Apply knowledge gained to daily clinical practice in BPH management.

## Session V - Men's Health Luncheon Symposium

An Update in Men's Health for Urology Residents and Trainees

At the end of the Men's Health Luncheon Symposium, participants should be able to:

- · Recall the diagnostic workup of patients with common men's health issues
- · Describe the management of common men's health issues
- Examine techniques for placing an inflatable penile prosthesis and artificial urinary sphincter and avoiding device infection

Target audience: residents and young urologists

SIU Regional Meetings in Urological Care: Evidence Based Updates



المراب ال





## June 10-12, 2022 / Istanbul

## Opportunities for Partnership

Sponsor Benefits	Gold Sponsor €35,000	Silver Sponsor €20,000	Bronze Sponsor €15,000	Exhibitor €2,000- 3,000
Meeting website—recognition through corporate logo on the designated Sponsor Acknowledgments section	<b>✓</b>	<b>✓</b>	<b>✓</b>	<b>✓</b>
Meeting virtual portal—recognition through corporate logo on the designated Sponsor Acknowledgments tab	<b>✓</b>	<b>✓</b>	<b>✓</b>	<b>✓</b>
Meeting mobile app—recognition through corporate logo in Sponsor Acknowledgements tab	<b>✓</b>	<b>✓</b>	<b>✓</b>	<b>✓</b>
Final Programme Digital Booklet— recognition through corporate logo in the designated Sponsor Acknowledgments section	<b>~</b>	<b>~</b>	<b>~</b>	<b>~</b>
Final Programme Digital Booklet—Full page, four color Corporate advertisement, NO product ads in the designated Industry-supported Activities section	<b>~</b>			
Virtual Delegate bag insert – 1 page PDF submitted by sponsor	<b>~</b>	<b>~</b>		
Exhibit Space (bare space)	18m²	12m²	6m²	6m²
Exhibit Space (shell scheme/table top)	<b>✓</b> Shell scheme	<b>✓</b> Shell scheme	<b>✓</b> Shell scheme	<b>✓</b> Table top
Sponsored Symposia (upon approval by programme committee; faculty travel and accommodations not included)	<b>✓</b>			
Exhibitor registrations	6	4	2	2
Meeting room for up to 90-minute hands-on training workshops or courtesy suite (workshops must be submitted to organizers for review and scheduling considerations)	•	<b>~</b>		
Social media (Facebook and Twitter)— Recognition of support through corporate name	<b>✓</b>	<b>✓</b>	<b>✓</b>	<b>✓</b>
On-site supporter recognition—through corporate logo in the exhibit hall and designated areas	<b>✓</b>	<b>✓</b>	<b>✓</b>	
Priority selection of symposia* and/or workshop** timeslots and exhibit booth location	<b>~</b>			

SIU Regional Meetings in Urological Care: Evidence Based Updates

Autol lite Autol lette Autol lette Autol



Auto Date A de la constante de la constante de la constante de la constante de la constante de la constante de





Virtual Exhibit Bo	oth 🗸	<b>✓</b>	<b>✓</b>	<b>✓</b>
À la Carte Opportunities				
*Satellite Symposium  45-60 minutes				
**Workshop  Room rental Audiovisual equipment Announcement of the session of Event mobile app Assistance with course promotion logistics Certificates of attendance, and	on, registration, and		€ 4,000	
<ul> <li>In-Programme Session</li> <li>Acknowledgement of sponsors</li> <li>Recognition on the Event websisite at the event (in select areas</li> </ul>	te, the Event mobile	me brochure app and on-	€ 5,000/session (unrestricted g	
<ul><li>ePosters</li><li>Acknowledgement of sponsors</li><li>Company logo on ePoster wall</li></ul>	nip in final programr	me brochure	€ 5,000	
Sponsorship of the virtual platform  • Acknowledgement on the virtual Sponsor Acknowledgments tab	al platform login pag	ge in the	€ 5,000	
<ul> <li>Sponsorship of the mobile app</li> <li>Acknowledgement on the mobile (no corporate logo) and in the State of the state</li></ul>		ments tab	€ 4,000	
Charging Corners  • Company logo on charging stat exhibit hall	ons available for de	legates in the	€ 6,000	
Sponsorship of the live translation (Spanish and French)	on the virtual plat	form	€ 1,500/langua € 2,500 for bo	age th languages
Sponsorship of invited speaker			€ 1,500 € 4,000	
Insert in the Virtual Delegate Bag			€ 2,000	
Badge Lanyards			€ 2,000	

SIU Regional Meetings in Urological Care: Evidence Based Updates

June 10-12, 2022 / Istanbul



Lilland Andre Control of the Control






## Exhibit Hall Schedule

	Date	Time (TRT [UTC +3])
Set-up	June 9, 2022	18:00 - 22:00
	June 10, 2022	11:00 - 18:00
Exhibit Hours	June 11, 2022	09:00 - 18:00
	June 12, 2022	09:00 - 14:00
Dismantling	June 12, 2022	14:00

## Exhibit Hall Floor Plan









## Participant Registration Fees

المرا المعلوا الراب المعلولات

Registration Category	EARLY Until March 31, 2022	LATE After April 1, 2022
Urologists and Specialists	€ 450,00	€ 500,00
Trainee, Residents, Nurses, Technicians	€ 250,00	€ 300,00
Host Country Participants	€ 400,00	€ 400,00
Virtual registration	€ 150,00	€ 150,00

## Group Registration

- · Group registration is available for a minimum of 10 in-person delegates.
- Please communicate with the Meeting Organizing Bureau for more information and to register your group.

## Meeting Organizing Bureau

### **BROS Congress, Incentive & Events**



Sağlam Fikir Sok. Esen Palas Apt. A Blok No: 2 D: 9 Şişli / İstanbul E-mail: bilge.yuksel@brosgroup.net

SIU Regional Meetings in Urological Care: Evidence Based Updates







## Sponsorship Reservation Form

## COMPANY'S REPRESENTATIVE DETAILS - INVOICING DETAILS INVOICE ADDRESS - PLEASE USE BLOCK LETTERS Name of company \_\_ Contact person \_\_\_ Address \_\_\_\_\_ Country \_\_\_\_ City Phone E-mail VAT No Company Activity We would like to book the following Sponsor items: \_\_\_\_€ \_\_\_\_€\_\_ € \_\_\_\_ \_\_\_\_\_€ \*Please add VAT 18% where applicable **Terms of Payment** The full payment shall be made 30 days before the starting date of the Meeting. **Cancellation Policy** Cancellations must be received in writing. A cancellation charge of 50% of total sponsorship fees will apply to cancellations received between 3 months and 1 month prior to the meeting. For cancellations received later than 4 weeks prior to the meeting a 100% charge of the application will be applied. Please return this form to: **BROS Congress, Incentive & Events** Esentepe Mah. Sağlam Fikir Sok. Esen Palas Apt. A Blok No: 2 D: 9 Esentepe / Şişli / İstanbul E-mail: bilge.yuksel@brosgroup.net Signature of this form implies compliance with the rules stated in this document. Signature: \_\_\_\_\_ Date: \_\_\_\_ This application is legally binding

ر الفيار الأمارية المنظم المنظم المنظم المنظم المنظم المنظم المنظم المنظم المنظم المنظم المنظم المنطق المنظم المنطق المنط

## Appendix A Programme Agenda and Invited Faculty



المراب المرابع





## Programme

All timing is listed in TRT (UTC+3)

June 10, 2	2022 - Friday
Session I	- Endourology  Plenary Room (Ballroom B)
12:45-13:00	Welcome - Jean de la Rosette (Turkey)
13:00-14:30	Semi Live Session: How I Do It/Points of Technique  Moderators: Vitor Cavadas (Portugal) - Anastasios Anastasiadis (Greece) - Ilker Seckiner (Turkey)
	<ul> <li>Procedure I - Impacted proximal ureter stone - Nadia Abid (France)</li> <li>Procedure II - Lower pole stone 1 cm - Vincent Estrade (France)</li> <li>Procedure III - Staghorn stone - Stylianos Giannakopoulos (Greece)</li> <li>Procedure IV - Stone in calyx diverticula - Vincent de Coninck (Belgium)</li> <li>Procedure V - Stone in Ectopic kidney - Ioannis Kartalas Goumas (Italy)</li> </ul>
14:30-16:00	Evidence-Based/Guidelines Session: How to Best Treat!  Moderators: Ioannis Kartalas Goumas – Nadia Abid - Ömer Levent Tuncay (Turkey)  Impacted proximal ureter stone - Vincent Estrade  Lower pole stone - Vincent de Coninck  Staghorn stone - Vitor Cavadas  Stone in calyx diverticula - Anastasios Anastasiadis  Stone in ectopic kidney - Stylianos Giannakopoulos
16:00-16:30	Coffee break (Ballroom A & Foyer)
16:30-17:00	Debate Session: Is Mini PCNL Going to Fade Away?  Moderators: Ahmet Yaser Müslümanoğlu (Turkey) - Emrah Yürük (Turkey) - Ioannis Kartalas Goumas  PRO - Nadia Abid CON - Ranan Dasgupta (United Kingdom)
17:00-18:00	Masters of Disaster Session  Moderators: Athanasios Papatsoris - Jean de la Rosette  Panel: Görkem Özenç (Turkey) - Anastasios Anastasiadis - Stylianos Giannakopoulos - Nadia Abid - Vitor Cavadas - Ömer Levent Tuncay
18:00-18:15	Future Perspectives Session  • Artificial Intelligence and Stone Management - Vincent Estrade

Appendix A – Programme Agenda







June 11, 2	June 11, 2022 - Saturday		
Session I	I – Oncology – Prostate Cancer Plenary Room (Ballroom B)		
07.45.00.00			
07:45-08:00	Welcome - Jean de la Rosette (Turkey)		
08:00-09:30	Semi-Live Session: How I Do It/Points of Technique  Moderators: Avelino Fraga (Portugal) - Franck Bladou (France) - Selami Albayrak (Turkey)  Procedure I - Prostate Biopsy - Petr Macek (France)  Procedure II - Focal Therapy I - Jurgen Fütterer (The Netherlands)  Procedure III - Focal Therapy II - José Luis Domínguez-Escrig (Spain)  Procedure IV - Robotic RP - Jochen Walz (France)  Procedure V - Salvage RP - Georg Salomon (Germany)  Procedure VI - Transperineal RP - Volkan Tuğcu (Turkey)		
09:30-11:00	Evidence-Based/Guidelines Session: How to Best Treat!		
	Moderators: Miguel Ramirez Backhaus (Spain) - Erdem Canda (Turkey) - Jurgen Fütterer (Netherlands)  • Prostate Biopsy - Jochen Walz  • Focal Therapy I - Petr Macek  • Focal Therapy II - Georg Salomon  • Robotic RP - Jose Luis Dominguez  • Salvage RP - Vincenzo Ficarra (Italy)  • Transperineal RP - Rahim Horuz (Turkey)		
11:00-11:30	Coffee break (Ballroom A & Foyer)		
11:30-12:00	Debate Session: Fusion versus Cognitive Biopsies Is the New Gold Standard  Moderators: Vincenzo Ficarra (Italy) - Bülent Akduman (Turkey)  • PRO Fusion/Cognitive - Paolo Gontero (Italy)  • CON Fusion/Cognitive – Jurgen Fütterer		
12:00-13:00	Masters of Disaster Session		
	Moderators: Franck Bladou - Georg Salomon Panel: Mehmet Özalevli (Turkey), Mutlu Ateş (Turkey), Avelino Fraga (Portugal), Behzat Ayubov (Uzbekistan), Vincenzo Ficarra - Paolo Gontero		
13:00-13:15	Future Perspectives Session  • 3D reconstruction and virtual RP - Cristian Fiori (Italy)		
13:15-14:00	Lunch (Ballroom A & Foyer)		
	• /		

Appendix A – Programme Agenda







## June 11, 2022 - Saturday Session III – Oncology – Bladder Cancer

Plenary Room (Ballroom B)

14:00-15:30	Semi-Live Session: How I Do It/Points of Technique
	Moderators: Miguel Ramirez Backhaus (Spain) - Pilar Lagu

Moderators: Miguel Ramirez Backhaus (Spain) - Pilar Laguna (Turkey) - Bülent Altay (Turkey)

- Procedure I TURBT en bloc Jose Maria Gaya Sopena (Spain)
- Procedure II TURBT under Image 1S Manuel Oliveira (Portugal)
- Procedure III UTUC and bladder cuff Vincenzo Ficarra (Italy)
- Procedure IV UTUC in solitary kidney Joyce Baard (The Netherlands)
- Procedure V Robotic orthotopic neobladder *Derya Balbay (Turkey)*

## 15:30-17:00 Evidence-Based/Guidelines Session: How to Best Treat!

Moderators: Nick Crisan (Romania) - Cristian Fiori (Italy) - İsmet Yavaşcaoğlu (Turkey)

- TURBT en bloc Yiğit Akın (Turkey)
- TURBT under enhance imaging (PDD/NBI/Image 1S) Fuat Kızılay (Turkey)
- UTUC and bladder cuff Piotr Chlosta (Poland)
- UTUC in solitary kidney Vitor Cavadas (Portugal)
- Bladder sparing protocols Öztuğ Adsan (Turkey)

### 17:00-17:30 Coffee break (Ballroom A & Foyer)

### 17:30-18:00 Debate Session - Is TURBT en bloc the New Gold Standard?

Moderators: Pilar Laguna - Alexey Martov (Russia) - Lukas Lusuardi (Austria)

- PRO Thomas Herrmann (Switzerland)
- CON Paolo Gontero (Italy)

### 18:00-19:00 Masters of Disaster Session

Moderators: Paolo Gontero - Jose Maria Gaya Sopena

Panel: İlham Ahmedov (Azerbaijan) - Nick Crisan - Pilar Laguna - Archil Chkhotua (Georgia) - Tarik Esen (Turkey) - Manuel Oliveira

### 19:00-19:15 Future Perspectives Session

MRI staging of bladder TCC - VI-RADS - Barış Bakır (Turkey)

Appendix A – Programme Agenda







June 12, 2 Session I	2022 - Sunday V – BPH  Plenary Room (Ballroom B)
07:45-08:00	Welcome - Jean de la Rosette (Turkey)
08:00-09:30	Semi-Live Session: How I Do It/Points of Technique  Moderators: Luis Campos-Pinheiro (Portugal) - Bulent Erkurt (Turkey) - Archil Chkhotua (Georgia)  • Procedure I - BiEEP - Giorgio Bozzini (Italy)  • Procedure II - Thulep - Thomas Herrmann (Switzerland)  • Procedure III - Water vapour - Lukas Lusuardi (Austria)  • Procedure IV - Aquablation - Ranan Dasgupta (United Kingdom)  • Urolift - Petros Tsafrakidis (Cyprus)
09:30-11:00	Evidence-Based/Guidelines Session: How to best treat!  Moderators: Cosimo de Nunzio (Italy) - Cevdet Çuni (Kosovo) - Athanasios Papatsoris (Greece)  BIEEP - Ahmed M Elshal (Egypt)  Thulep - Joao Cabral (Portugal)  Water vapour - Burak Turna (Turkey)  Aquablation - Albert El Hajj (Lebanon)  Procedure V - Urolift - Mauro Gacci (Italy)
11:00-11:30	Coffee break (Ballroom A & Foyer)
11:30-12:00	Debate Session: Is Preservation of Ejaculatory Function Relevant?  Moderators: Joao Cabral - Zufar Khakimkhodzhaev (Kyrgyzstan) - Anuar Anuvar (Kazakhstan)  PRO - Ates Kadioglu (Turkey) CON - Thomas Herrmann
12:00-13:00	Masters of Disaster Session  Moderators: Ranan Dasgupta - Mauro Gacci  Panel: Cosimo de Nunzio - Giorgio Bozzini - Ahmed M Elshal (Egypt) - Petros Tsafrakidis (Cyprus) - Bulent Erkurt (Turkey)
13:00-13:15	Future Perspectives Session  Is individualised care the future of LUTS/BPO management?  Stavros Gravas (Cyprus)
13:15-13:20	Closing Remarks Jean de la Rosette
13:20-14:00	Lunch (Ballroom A & Foyer)

Appendix A – Programme Agenda

Auto Liste A Auto Liste A List







## June 12, 2022 - Sunday

## Session V - Men's Health Luncheon Symposium: An Update in Men's Health for Urology Residents and Trainees

7		
71	700	nr.
	ızm	ш
١.		

13:30- 13:32	Welcome & Introduction Faysal Yafi (USA)
13:32-13:42	Upgrading the Clinical Practice by setting up a Men's Health Clinic Rajeev Sood (India)
13:42-13:54	Hypogonadism: from diagnosis to management Faysal Yafi (USA)
13:54-14:06	Management of stable phase Peyronie's disease  Abdel Rahman Zahran, Egypt
14:06-14:21	Management of post-prostatectomy climacturia  Faysal Yafi
14:21-14:31	Q&A session
14:31-14:44	Surgical treatment of varicocele: which approach is best?  Ates Kadioglu (Turkey)
14:44-14:56	Surgical management of priapism  Ates Kadioglu
14:56-15:08	Penile fracture: diagnosis and management  Ates Kadioglu
15:08-15:18	Q&A session
15:18-15:30	Setting up a penile implant centre  Koenraad van Renterghem (Belgium)
15:30-15:42	Step-by-step approach to IPP placement Koenraad van Renterghem
15:42-15:54	IPP infection prevention and treatment strategies  Koenraad van Renterghem
15:54-16:00	Q&A session
16:00	Closing remarks Faysal Yafi

Appendix A – Programme Agenda

## Appendix B Literature Review

Autolite A Autoliteurs | Land







## Stone Disease

The prevalence of urinary stones has increased over the past few years, with the majority of new cases corresponding to stones in the upper urinary tract.<sup>4</sup> While in the past urinary stones were primarily managed through open surgery, great advances have been made over the years in the development of minimally invasive interventions and surgical techniques to treat this condition. Current management options include shockwave lithotripsy (SWL) or endourological procedures, i.e. ureteroscopy (URS) and percutaneous nephrolithotomy (PCNL).<sup>5</sup> Factors guiding the selection of management approach include the location and size of the stone, whereas stone composition and patient- and/or organ-specific factors may also inform contraindications for treatment with different interventions.<sup>6</sup> More recently, technological advances in artificial intelligence have demonstrated positive prospects not only in treatment selection and outcome prediction but also supporting the diagnosis and prevention of urinary stones.<sup>7</sup>

## Prostate Cancer

Prostate cancer ranks as the second most frequently diagnosed malignancy in men, with more than 1.4 million new cases in 2020. In the same year, prostate cancer deaths exceeded 375,000 worldwide.<sup>8</sup> Most deaths occur after progression to advanced disease states.<sup>9</sup> As a result, it is imperative that prostate cancer be detected early, and that appropriate management be initiated to prevent progression to more difficult to treat states. Transrectal ultrasound (TRUS)-guided prostate needle biopsy remains the gold standard for the diagnosis of prostate cancer. However, non-targeted TRUS risks both over diagnosing indolent cancers and missing aggressive disease.<sup>10</sup> Advances in magnetic resonance imaging (MRI) technology have allowed for the development of targeted MRI-TRUS fusion biopsy<sup>11</sup> as well as multiparametric MRI (mpMRI)-guided biopsy, which have been shown to improve the ability to detect significant cancer and decrease detection of indolent cancers.<sup>12</sup>

For patients requiring active treatment, radical prostatectomy is associated with good oncologic control, but may result in important morbidity.<sup>13</sup> Over the years, surgical approaches have evolved from open procedures to laparoscopic and robotic-assisted techniques that may offer potential for improved preservation of sexual and urinary function.<sup>14</sup> More recently, 3D reconstruction based on mpMRI and real-time superimposed imaging has shown positive outcomes during augmented reality robot-assisted radical prostatectomy.<sup>15</sup> Opportunities to treat early disease with a more focal approach are also being actively pursued, with the goal to minimize treatment toxicity. <sup>16</sup> Several energy sources for focal therapy have been investigated in the last several years, including high-intensity focused ultrasound (HIFU), focal laser ablation (FLA), vascular-targeted photodynamic therapy (PDT), irreversible electroporation (IRE), and focal cryotherapy.<sup>17</sup>

## Bladder Cancer and Upper Tract Urothelial Carcinoma

Bladder cancer is the most common urothelial malignancy, with over 573,00 new cases and almost 213,000 deaths estimated worldwide in 2020.8 Approximately 70% of those new cases correspond to non-muscle-invasive bladder cancer (NMIBC). 18 The initial steps in the diagnosis and management of NMIBC involve visualization of the bladder by cystoscopy and the complete removal of all visible lesions with transurethral resection of bladder tumour (TURBT). 19 In recent years, novel strategies

Appendix B - Literature Review

## SIU Regional Meeting in Urological Care

المرابع المراب



الأعلى والأواري





have been developed to improve initial management of NMIBC. These strategies include new visualization approaches with photodynamic diagnosis (PDD)<sup>20,21</sup> and narrow-band imaging (NBI),<sup>22,23</sup> which have demonstrated positive outcomes in targeting biopsies. Improvements in instrumentation and technique for tumour resection have also been developed with en bloc TURBT, which may provide superior outcomes compared to conventional TURBT.<sup>24</sup> For patients presenting with muscle-invasive bladder cancer (MIBC), which accounts for approximately 20% of newly diagnosed cases, radical cystectomy is the standard treatment in many countries.<sup>25</sup> In these patients, orthotopic neobladder (ONB) is used to reconstruct an urinary reservoir that allows for a diverted urinary tract. <sup>26</sup> In many centres, ONB has been increasingly performed with robotic assistance.<sup>27,28</sup> Treatment decision-making in bladder cancer may be informed by disease staging, which may be performed with mpMRI.<sup>29</sup> To standardize MRI acquisition and interpretation, the Vesical Imaging Reporting and Data System (VI-RADS) score was developed in 2018 and has since been validated across several institutions.<sup>30</sup>

Upper tract urothelial carcinoma (UTUC) is an uncommon form of cancer accounting for 5%–10% of all UCs.<sup>31</sup> UTUC affects the ureter and pyelocaliceal cavities and is considered challenging to manage, given its aggressive features and prevalence in elderly and comorbid patients.<sup>32,33</sup> The contemporary treatment of UTUC depends on the disease stage and prognostic risk. For patients with low-risk localized UTUC, kidney-sparing surgery has emerged as an option to reduce the morbidity associated with radical nephroureterectomy, without compromising outcomes.<sup>34</sup> By contrast, open radical nephroureterectomy is the gold standard for treating high-risk UTUC,<sup>32</sup> although laparoscopic and robot-assisted approaches may also be considered.

## Benign Prostatic Hyperplasia

BPH is the most common underlying cause of lower urinary tract symptoms (LUTS) in elderly men.35 Endoscopic enucleation of the prostate (EEP) is among the main surgical management approaches for BPH.36 Commonly used techniques include bipolar EEP (BiEEP) using a bipolar electrosurgical unit as energy source<sup>37</sup> or laser EEP with holmium (HoLEP), thulium (ThuLEP), and diode laser systems (DiLEP).36 These approaches may provide some advantages over traditional transurethral resection of the prostate (TURP) to manage BPH.36 In recent years, minimally invasive interventions for LUTS due to BPH have become the focus of increased research. Prostatic urethral lift (UroLift<sup>™</sup>, manufactured by NeoTract) is a novel technique performed in the outpatient setting. A small, transprostatic permanent implant is delivered through the urethra, keeping the prostatic lobes under traction and maintaining the prostatic urethra open.<sup>38</sup> The procedure does not involve tissue removal or ablation and can be performed under local anesthesia. Water vapour therapy (Rezum™, manufactured by Boston Scientific) uses thermal energy in the form of water vapour to ablate prostatic tissue transurethrally via cystoscopy.<sup>39</sup> The procedure is performed without the need of general anesthesia and patients can be released the same day. Lastly, Aquablation™ is a novel, robotic-assisted technique that uses high-pressure saline to resect prostate tissue.<sup>40</sup> Some advantages of this technique include a fast resection time (<10 minutes), preservation of sexual function, and reduction of urinary symptoms. 40,41

Appendix B - Literature Review



الأعلى وأبال والمر





## References

- 1. Donlon E. Lost and found: the academic conference in pandemic and post-pandemic times. *Irish Educational Studies*. 2021;40(2):367-373. doi:10.1080/03323315.2021.1932554
- Hameed BZ, Tanidir Y, Naik N, et al. Will "hybrid" meetings replace face-to-face meetings post COVID-19 era? perceptions and views from the urological community. Urology. 2021;156:52-57. doi:10.1016/J. UROLOGY.2021.02.001/ATTACHMENT/698290B9-B733-42D2-ADDD-5BB84C6AFE24/MMC5.DOCX
- 3. Newman TH, Sa Green J. Hybrid urology conferences: using innovation and new approaches. *Trends in Urology & Men's Health.* 2021;12(4):24-26. doi:10.1002/TRE.812
- 4. Santos JMR. Ureteroscopy from the recent past to the near future. *Urolithiasis 2017 46:1.* 2017;46(1):31-37. doi:10.1007/S00240-017-1016-8
- 5. Geraghty RM, Jones P, Somani BK. Worldwide trends of urinary stone disease treatment over the last two decades: a systematic review. *Journal of Endourology*. 2017;31(6):547-556. doi:10.1089/end.2016.0895
- 6. Türk C, Neisius A, Petřík A, et al. EAU Guidelines on Urolithiasis. Published 2021. Accessed June 22, 2021. https://uroweb.org/guideline/urolithiasis/
- 8. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for Clinicians*. 2021;71(3):209-249. doi:10.3322/caac.21660
- 9. Swami U, McFarland TR, Nussenzveig R, et al. Advanced prostate cancer: treatment advances and future directions. *Trends in Cancer*. 2020;6(8):702-715. doi:10.1016/J.TRECAN.2020.04.010
- 10. Descotes JL. Diagnosis of prostate cancer. Asian Journal of Urology. 2019;6(2):129-136. doi:10.1016/j. ajur.2018.11.007
- 11. Hansen N, Patruno G, Wadhwa K, et al. Magnetic resonance and ultrasound image fusion supported transperineal prostate biopsy using the Ginsburg protocol: technique, learning points, and biopsy results. *European Urology*. 2016;70(2):332-340. doi:10.1016/j.eururo.2016.02.064
- 12. Drost FJH, Osses D, Nieboer D, et al. Prostate magnetic resonance imaging, with or without magnetic resonance imaging-targeted biopsy, and systematic biopsy for detecting prostate cancer: a Cochrane systematic review and meta-analysis. *European Urology*. 2020;77(1):78-94. doi:10.1016/j.eururo.2019.06.023
- 13. Donovan JL, Hamdy FC, Lane JA, et al. Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. *The New England Journal of Medicine*. 2016;375(15):1425-1437. doi:10.1056/NEJMOA1606221
- 14. Basiri A, de la Rosette JJ, Tabatabaei S, Woo HH, Laguna MP, Shemshaki H. Comparison of retropubic, laparoscopic and robotic radical prostatectomy: who is the winner? *World Journal of Urology*. 2018;36(4):609-621. doi:10.1007/S00345-018-2174-1/FIGURES/3
- 15. Porpiglia F, Checcucci E, Amparore D, et al. Augmented-reality robot-assisted radical prostatectomy using hyper-accuracy three-dimensional reconstruction (HA3D™) technology: a radiological and pathological study. *BJU International*. 2019;123(5):834-845. doi:10.1111/BJU.14549
- 16. Polascik TJ, Mouraviev V. Focal therapy for prostate cancer is a reasonable treatment option in properly selected patients. *Urology*. 2009;74(4):726-730. doi:10.1016/J.UROLOGY.2009.02.084
- 17. Tourinho-Barbosa RR, Wood BJ, Abreu AL, et al. Current state of image-guided focal therapy for prostate cancer. World Journal of Urology 2020 39:3. 2020;39(3):701-717. doi:10.1007/S00345-020-03254-4

Appendix B – Literature Review

## SIU Regional Meeting in Urological Care



ر فیلیما الیان





- 18. Kirkali Z, Chan T, Manoharan M, et al. Bladder cancer: Epidemiology, staging and grading, and diagnosis. *Urology*. 2005;66(6 SUPPL. 1):4-34. doi:10.1016/j.urology.2005.07.062
- 19. Lenis AT, Lec PM, Chamie K. Bladder cancer a review. *JAMA Journal of the American Medical Association*. 2020;324(19):1980-1991. doi:10.1001/jama.2020.17598
- 20. Mowatt G, N'Dow J, Vale L, et al. Photodynamic diagnosis of bladder cancer compared with white light cystoscopy: Systematic review and meta-analysis. *International Journal of Technology Assessment in Health Care*. 2011;27(1):3-10. doi:10.1017/S0266462310001364
- 21. Rolevich AI, Zhegalik AG, Mokhort AA, et al. Results of a prospective randomized study assessing the efficacy of fluorescent cystoscopy-assisted transurethral resection and single instillation of doxorubicin in patients with non-muscle-invasive bladder cancer. *World Journal of Urology.* 2017;35(5):745-752. doi:10.1007/S00345-016-1927-Y/FIGURES/3
- 22. Drejer D, Béji S, Munk Nielsen A, et al. Clinical relevance of narrow-band imaging in flexible cystoscopy: the DaBlaCa-7 study. Scandinavian Journal of Urology. 2017;51(2):120-123. doi:10.1080/21681805.2017.1295101
- 23. Kim S bin, Yoon SG, Tae J, et al. Detection and recurrence rate of transurethral resection of bladder tumors by narrow-band imaging: Prospective, randomized comparison with white light cystoscopy. *Investigative and Clinical Urology.* 2018;59(2):98-105. doi:10.4111/ICU.2018.59.2.98
- 24. Zhang D, Yao L, Yu S, et al. Safety and efficacy of en bloc transurethral resection versus conventional transurethral resection for primary nonmuscle-invasive bladder cancer: A meta-analysis. *World Journal of Surgical Oncology*. 2020;18(1):1-12. doi:10.1186/S12957-019-1776-4/FIGURES/5
- 25. Patel VG, Oh WK, Galsky MD. Treatment of muscle-invasive and advanced bladder cancer in 2020. CA: A Cancer Journal for Clinicians. 2020;70(5):404-423. doi:10.3322/caac.21631
- 26. Qu L, Lawrentschuk N. Orthotopic neobladder reconstruction: Patient selection and perspectives. *Research and Reports in Urology*. 2019;11:333-341. doi:10.2147/RRU.S181473
- 27. Chopra S, de Castro Abreu AL, Berger AK, et al. Evolution of robot-assisted orthotopic ileal neobladder formation: a step-by-step update to the University of Southern California (USC) technique. *BJU International*. 2017;119(1):185-191. doi:10.1111/BJU.13611
- 28. Minervini A, Vanacore D, Vittori G, et al. Florence robotic intracorporeal neobladder (FloRIN): a new reconfiguration strategy developed following the IDEAL guidelines. *BJU International*. 2018;121(2):313-317. doi:10.1111/BJU.14077
- 29. Pecoraro M, Takeuchi M, Vargas HA, et al. Overview of VI-RADS in Bladder Cancer. *American Journal of Radiology*. 2020;214(6):1259-1268. doi:10.2214/AJR.20.22763
- 30. Panebianco V, Narumi Y, Altun E, et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System). *European Urology*. 2018;74(3):294-306. doi:10.1016/J.EURURO.2018.04.029
- 31. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA: A Cancer Journal for Clinicians. 2021;71(1):7-33. doi:10.3322/CAAC.21654
- 32. Rouprêt M, Babjuk M, Burger M, et al. EAU Guidelines on Upper Urinary Tract Urothelial Carcinoma. European Association of Urology. Published 2021. Accessed July 7, 2021. https://uroweb.org/guideline/upper-urinary-tract-urothelial-cell-carcinoma/
- 33. Taylor J, Meng X, Ghandour R, Margulis V. Advancements in the clinical management of upper tract urothelial carcinoma. *Expert Review of Anticancer therapy*. 2019;19(12):1051-1060. doi:10.1080/14737140.2019.1698295
- 34. Seisen T, Peyronnet B, Dominguez-Escrig JL, et al. Oncologic outcomes of kidney-sparing surgery versus radical nephroureterectomy for upper tract urothelial carcinoma: a systematic review by the EAU Non-Muscle Invasive Bladder Cancer Guidelines Panel. *European Urology*. 2016;70(6):1052-1068. doi:10.1016/J. EURURO.2016.07.014

Appendix B – Literature Review

الأعلى الأعلى الأعلى الأعلى الأعلى الأعلى الأعلى الأعلى الأعلى الأعلى الأعلى الأعلى الأعلى الأعلى الأعلى الأعلى



افعارها الراء





- 35. Sivarajan G, Borofsky MS, Shah O, Lingeman JE, Lepor H. The role of minimally invasive surgical techniques in the management of large-gland benign prostatic hypertrophy. *Rev Urol.* 2015;17(3):140-149. doi:10.3909/riu0675
- 36. Huang SW, Tsai CY, Tseng CS, et al. Comparative efficacy and safety of new surgical treatments for benign prostatic hyperplasia: Systematic review and network meta-analysis. *The BMJ.* 2019;367:l5919-l5919. doi:10.1136/bmj.l5919
- 37. Ryang SH, Ly TH, Tran AV, et al. Bipolar enucleation of the prostate—step by step. *Andrologia*. 2020;52(8):e13631. doi:10.1111/AND.13631
- 38. Jones P, Rai BP, Aboumarzouk O, et al. UroLift: a new minimally-invasive treatment for benign prostatic hyperplasia. *Therapeutic advances in urology*. 2016;8(6):372-376. doi:10.1177/1756287216671497
- 39. Westwood J, Geraghty R, Jones P, et al. Rezum: a new transurethral water vapour therapy for benign prostatic hyperplasia. *Therapeutic Advances in Urology*. 2018;10(11):327-333. doi:10.1177/1756287218793084
- 40. Taktak S, Jones P, Haq A, et al. Aquablation: a novel and minimally invasive surgery for benign prostate enlargement. *Therapeutic Advances in Urology*. 2018;10(6):183-188. doi:10.1177/1756287218760518
- 41. Gilling P, Reuther R, Kahokehr A, et al. Aquablation Image-guided robot-assisted waterjet ablation of the prostate: Initial clinical experience. *BJU International*. 2016;117(6):923-929. doi:10.1111/bju.13358



## SAVE THE DATE

Join the International Urology Community in Montreal, Canada

November 9-13, 2022



42nd Congress of the Société Internationale D'Urologie

Palais des congrès de Montréal



www.siu-urology.org

in f 🛩 #9

#SIUWorld #SIU2022



EVENT SECRETARIAT

BROS Congress, Incentive & Events

Bilge Yuksel

bilge.yuksel@brosgroup.net Esentepe Mah. Sağlam Fikir Sok. Esen Palas Apt. A Blok No: 2 D: 9 Esentepe / Şişli / İstanbul Tel: +90 (212) 296 66 70

Faks: +90 (212) 296 66 71



